A Comparison of Prognostic Models to Facilitate Surgical Decision Making for Patients with Spinal Metastatic Disease

Survival prognosis in an important factor to consider when implementing surgical treatment for metastatic spine disease. Several scoring systems have been developed to help providers predict survival and determine which patients with metastatic spine disease are candidates for surgery.Our primary aim was to determine predictors of 3-month, 6-month, and overall survivorship followingsurgery for metastatic spine disease.Our secondary aim was to identify the scoringsystem which most accurately predicts the short-term life expectancy of patients undergoingsurgery for metastatic spine lesions

Search for Neutral Higgs Bosons in Events with Multiple Bottom Quarks at the Tevatron

The combination of searches performed by the CDF and D0 collaborations at the Fermilab Tevatron Collider for neutral Higgs bosons produced in association with b quarks is reported. The data, corresponding to 2.6 fb-1 of integrated luminosity at CDF and 5.2 fb-1 at D0, have been collected in final states containing three or more b jets. Upper limits are set on the cross section multiplied by the branching ratio varying between 44 pb and 0.7 pb in the Higgs boson mass range 90 to 300 GeV, assuming production of a narrow scalar boson. Significant enhancements to the production of Higgs bosons can be found in theories beyond the standard model, for example in supersymmetry. The results are interpreted as upper limits in the parameter space of the minimal supersymmetric standard model in a benchmark scenario favoring this decay mode.Comment: 10 pages, 2 figure

Combination of the top-quark mass measurements from the Tevatron collider

The top quark is the heaviest known elementary particle, with a mass about 40 times larger than the mass of its isospin partner, the bottom quark. It decays almost 100% of the time to a $W$ boson and a bottom quark. Using top-antitop pairs at the Tevatron proton-antiproton collider, the CDF and {\dzero} collaborations have measured the top quark's mass in different final states for integrated luminosities of up to 5.8 fb$^{-1}$. This paper reports on a combination of these measurements that results in a more precise value of the mass than any individual decay channel can provide. It describes the treatment of the systematic uncertainties and their correlations. The mass value determined is $173.18 \pm 0.56 \thinspace ({\rm stat}) \pm 0.75 \thinspace ({\rm syst})$ GeV or $173.18 \pm 0.94$ GeV, which has a precision of $\pm 0.54$, making this the most precise determination of the top quark mass.Comment: 30 pages and 6 figures, published in Phys. Rev.

Hepatic Resection and Transplantation for Primary Carcinoid Tumors of the Liver

OBJECTIVE: To discuss the diagnosis and management of primary carcinoid tumors of the liver in light of our experience and a literature review. SUMMARY BACKGROUND DATA: Carcinoid tumors of the liver are rare and pose a diagnostic and management dilemma. This series is the largest reported and the only one to include liver transplantation as a treatment option. METHODS: Between March 1994 and May 2002, we treated 8 patients (4 male, 4 female) with primary hepatic carcinoid tumors. Carcinoid syndrome complicated only 1 of the cases. Treatment was by liver resection in 6 patients and orthotopic liver transplantation in 2. RESULTS: The diagnosis was confirmed histologically with light microscopy and immunohistochemistry in the absence of an alternative primary site. Six patients remain alive and disease free after follow-up of more than 3 years: 39, 43, 45, 50, 50, and 95 months. Two patients are recently postoperative. CONCLUSIONS: Active exclusion of an extrahepatic primary site is essential for the diagnosis of primary carcinoid of the liver. The mainstay of treatment should be liver resection, although liver transplantation may be considered in patients with widespread hepatic involvement. A radical surgical approach is warranted as this disease carries a better prognosis than for other primary hepatic tumors and for secondary hepatic carcinoids